• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Treatment of borderline personality disorder with risperidone.
【24h】

Treatment of borderline personality disorder with risperidone.

机译：利培酮治疗边缘性人格障碍。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Of the various Axis II disorders, borderline personality disorder (BPD) is among the more critical to treat. There are at present few results in terms of clinical outcome with the psychotropic agents available. Possible targets for pharmacotherapy are affective symptoms, cognitive disturbances, and impulsive, self-injurious behaviors. In previous studies, atypical antipsychotics at low-to-moderate doses provided symptom reduction with good tolerability. Our purpose was to assess the efficacy of risperidone in BPD, focusing on its effects on impulsive-aggressive behavior. METHOD: Fifteen BPD outpatients (DSM-IV diagnosis) with prominent histories of aggressive behavior were included in an 8-week open-label study with risperidone at low-to-moderate doses. Axis II codiagnoses included antisocial personality disorder (N = 4). Exclusion criteria included current Axis I diagnosis or any major medical or neurologic illness. Efficacy measures were the 21-item Hamilton Rating Scale for Depression, the Brief Psychiatric Rating Scale, the DSM-IV Global Assessment of Functioning, and the self-rated Aggression Questionnaire. Evaluations were carried out at baseline and at the end of the treatment. RESULTS: Thirteen patients completed the trial; 2 patients dropped out because of lack of compliance. Final mean dose of risperidone was 3.27 mg/day. There was a significant (p = .0057) reduction in aggression based on Aggression Questionnaire scores. This amelioration was coupled with an overall improvement, including a reduction in depressive symptoms and an increase in energy and global functioning. CONCLUSION: Risperidone at low-to-moderate doses can improve BPD symptomatology. Further studies are needed to explore the efficacy of risperidone versus placebo as well as in comparison to other potential treatments for BPD.
机译：背景：在各种Axis II疾病中，边缘性人格障碍（BPD）是最关键的治疗方法。就可用精神药物的临床结果而言，目前尚无结果。药物治疗的可能目标是情感症状，认知障碍和冲动性自我伤害行为。在先前的研究中，低剂量至中剂量的非典型抗精神病药可减轻症状并具有良好的耐受性。我们的目的是评估利培酮在BPD中的疗效，重点在于其对冲动攻击行为的影响。方法：在一项为期8周的开放标签研究中，以低剂量至中度剂量使用利培酮的15名BPD门诊患者（DSM-IV诊断）具有明显的攻击行为。 Axis II共同诊断包括反社会人格障碍（N = 4）。排除标准包括当前的Axis I诊断或任何重大医学或神经系统疾病。疗效指标包括21个项的汉密尔顿抑郁量表，简短的精神病量表，DSM-IV功能总体评估以及自我评估的攻击问卷。在基线和治疗结束时进行评估。结果：13名患者完成了该试验。 2名患者因缺乏依从性而退学。利培酮的最终平均剂量为3.27 mg / day。根据攻击问卷得分，攻击感显着降低（p = .0057）。这种改善与整体改善相结合，包括抑郁症状的减轻以及能量和整体功能的增强。结论：利培酮低至中剂量可改善BPD症状。需要进一步研究以探索利培酮与安慰剂的疗效以及与BPD的其他潜在治疗方法的比较。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号